Clinical presentation, management, and pathophysiology of neuropathic itch

Unlike conventional itch, neuropathic itch develops in normal skin from excess peripheral firing or dampened central inhibition of itch pathway neurons. Neuropathic itch is a symptom of the same central and peripheral nervous system disorders that cause neuropathic pain, such as sensory polyneuropat...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Lancet neurology 2018-08, Vol.17 (8), p.709-720
Hauptverfasser: Steinhoff, Martin, Schmelz, Martin, Szabó, Imre Lőrinc, Oaklander, Anne Louise
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page 720
container_issue 8
container_start_page 709
container_title Lancet neurology
container_volume 17
creator Steinhoff, Martin
Schmelz, Martin
Szabó, Imre Lőrinc
Oaklander, Anne Louise
description Unlike conventional itch, neuropathic itch develops in normal skin from excess peripheral firing or dampened central inhibition of itch pathway neurons. Neuropathic itch is a symptom of the same central and peripheral nervous system disorders that cause neuropathic pain, such as sensory polyneuropathy, radiculopathy, herpes zoster, stroke, or multiple sclerosis, and lesion location affects symptoms more than aetiology. The causes of neuropathic itch are heterogeneous, and thus diagnosis is based primarily on recognising characteristic, disease-specific clinical presentations. However, the diagnosis of neuropathic itch is challenging, different subforms exist (eg, focal vs widespread, peripheral vs central), and the mechanisms of neuropathic itch are poorly understood, resulting in reduced treatment availability. Currently available strategies include treating or preventing causal diseases, such as diabetes or herpes zoster, and topical or systemic medications that calm excess neuronal firing. Discovery of itch mediators such as gastrin releasing peptide, receptors (eg, neurokinin-1), and pathways (eg, Janus kinases) might encourage much needed new research into targeted treatments of neuropathic itch.
doi_str_mv 10.1016/S1474-4422(18)30217-5
format Article
fullrecord <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_2074122058</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S1474442218302175</els_id><sourcerecordid>2071125403</sourcerecordid><originalsourceid>FETCH-LOGICAL-c485t-38d34b8e7ceacb6881ad5ffa2820eb10dad88eff31c7d2840737618050f455e83</originalsourceid><addsrcrecordid>eNqFkE1P3DAQhq0KVGDbn1AUiQuVNtTjj8S3Cq1aCkLiQHu2vPaENUrsYCeV9t-T7G459MJpRq-e-dBDyBegV0Ch-vYIohalEIxdgvrKKYO6lB_I6SGu5NFbz9gJOcv5mU6QUPCRnHBKOacVnJK7VeuDt6Yt-oQZw2AGH8Oy6EwwT9hNwbIwwRW9GTax32yzj2182haxKQKOKc65t4Uf7OYTOW5Mm_HzoS7In58_fq9-lfcPN7er6_vSCiWHkivHxVphbdHYdaUUGCebxjDFKK6BOuOUwqbhYGvHlKA1rytQVNJGSImKL8jlfm-f4suIedCdzxbb1gSMY9aM1gIYo3JGL_5Dn-OYwvTdTAEwKSYRCyL3lE0x54SN7pPvTNpqoHqWrXey9WxSg9I72VpOc-eH7eO6Q_c29c_uBHzfAzjp-Osx6Ww9BovOJ7SDdtG_c-IVIUqNwA</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2071125403</pqid></control><display><type>article</type><title>Clinical presentation, management, and pathophysiology of neuropathic itch</title><source>MEDLINE</source><source>Elsevier ScienceDirect Journals</source><creator>Steinhoff, Martin ; Schmelz, Martin ; Szabó, Imre Lőrinc ; Oaklander, Anne Louise</creator><creatorcontrib>Steinhoff, Martin ; Schmelz, Martin ; Szabó, Imre Lőrinc ; Oaklander, Anne Louise</creatorcontrib><description>Unlike conventional itch, neuropathic itch develops in normal skin from excess peripheral firing or dampened central inhibition of itch pathway neurons. Neuropathic itch is a symptom of the same central and peripheral nervous system disorders that cause neuropathic pain, such as sensory polyneuropathy, radiculopathy, herpes zoster, stroke, or multiple sclerosis, and lesion location affects symptoms more than aetiology. The causes of neuropathic itch are heterogeneous, and thus diagnosis is based primarily on recognising characteristic, disease-specific clinical presentations. However, the diagnosis of neuropathic itch is challenging, different subforms exist (eg, focal vs widespread, peripheral vs central), and the mechanisms of neuropathic itch are poorly understood, resulting in reduced treatment availability. Currently available strategies include treating or preventing causal diseases, such as diabetes or herpes zoster, and topical or systemic medications that calm excess neuronal firing. Discovery of itch mediators such as gastrin releasing peptide, receptors (eg, neurokinin-1), and pathways (eg, Janus kinases) might encourage much needed new research into targeted treatments of neuropathic itch.</description><identifier>ISSN: 1474-4422</identifier><identifier>EISSN: 1474-4465</identifier><identifier>DOI: 10.1016/S1474-4422(18)30217-5</identifier><identifier>PMID: 30033061</identifier><language>eng</language><publisher>England: Elsevier Ltd</publisher><subject>Clinical trials ; Cytokines ; Dermatology ; Diabetes mellitus ; Diabetic neuropathy ; Diagnosis ; Disease Management ; Drugs ; Gastrin ; Herpes zoster ; Humans ; Multiple sclerosis ; Mutation ; Narcotics ; Nervous system ; Neuralgia - diagnosis ; Neuralgia - physiopathology ; Neuralgia - therapy ; Neurokinin ; Neurokinin NK1 receptors ; Peripheral neuropathy ; Polyneuropathy ; Pruritus ; Pruritus - diagnosis ; Pruritus - physiopathology ; Pruritus - therapy ; Skin ; Ulcers</subject><ispartof>Lancet neurology, 2018-08, Vol.17 (8), p.709-720</ispartof><rights>2018 Elsevier Ltd</rights><rights>Copyright © 2018 Elsevier Ltd. All rights reserved.</rights><rights>Copyright Elsevier Limited Aug 2018</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c485t-38d34b8e7ceacb6881ad5ffa2820eb10dad88eff31c7d2840737618050f455e83</citedby><cites>FETCH-LOGICAL-c485t-38d34b8e7ceacb6881ad5ffa2820eb10dad88eff31c7d2840737618050f455e83</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://www.sciencedirect.com/science/article/pii/S1474442218302175$$EHTML$$P50$$Gelsevier$$H</linktohtml><link.rule.ids>314,776,780,3537,27901,27902,65306</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/30033061$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Steinhoff, Martin</creatorcontrib><creatorcontrib>Schmelz, Martin</creatorcontrib><creatorcontrib>Szabó, Imre Lőrinc</creatorcontrib><creatorcontrib>Oaklander, Anne Louise</creatorcontrib><title>Clinical presentation, management, and pathophysiology of neuropathic itch</title><title>Lancet neurology</title><addtitle>Lancet Neurol</addtitle><description>Unlike conventional itch, neuropathic itch develops in normal skin from excess peripheral firing or dampened central inhibition of itch pathway neurons. Neuropathic itch is a symptom of the same central and peripheral nervous system disorders that cause neuropathic pain, such as sensory polyneuropathy, radiculopathy, herpes zoster, stroke, or multiple sclerosis, and lesion location affects symptoms more than aetiology. The causes of neuropathic itch are heterogeneous, and thus diagnosis is based primarily on recognising characteristic, disease-specific clinical presentations. However, the diagnosis of neuropathic itch is challenging, different subforms exist (eg, focal vs widespread, peripheral vs central), and the mechanisms of neuropathic itch are poorly understood, resulting in reduced treatment availability. Currently available strategies include treating or preventing causal diseases, such as diabetes or herpes zoster, and topical or systemic medications that calm excess neuronal firing. Discovery of itch mediators such as gastrin releasing peptide, receptors (eg, neurokinin-1), and pathways (eg, Janus kinases) might encourage much needed new research into targeted treatments of neuropathic itch.</description><subject>Clinical trials</subject><subject>Cytokines</subject><subject>Dermatology</subject><subject>Diabetes mellitus</subject><subject>Diabetic neuropathy</subject><subject>Diagnosis</subject><subject>Disease Management</subject><subject>Drugs</subject><subject>Gastrin</subject><subject>Herpes zoster</subject><subject>Humans</subject><subject>Multiple sclerosis</subject><subject>Mutation</subject><subject>Narcotics</subject><subject>Nervous system</subject><subject>Neuralgia - diagnosis</subject><subject>Neuralgia - physiopathology</subject><subject>Neuralgia - therapy</subject><subject>Neurokinin</subject><subject>Neurokinin NK1 receptors</subject><subject>Peripheral neuropathy</subject><subject>Polyneuropathy</subject><subject>Pruritus</subject><subject>Pruritus - diagnosis</subject><subject>Pruritus - physiopathology</subject><subject>Pruritus - therapy</subject><subject>Skin</subject><subject>Ulcers</subject><issn>1474-4422</issn><issn>1474-4465</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2018</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><sourceid>BENPR</sourceid><recordid>eNqFkE1P3DAQhq0KVGDbn1AUiQuVNtTjj8S3Cq1aCkLiQHu2vPaENUrsYCeV9t-T7G459MJpRq-e-dBDyBegV0Ch-vYIohalEIxdgvrKKYO6lB_I6SGu5NFbz9gJOcv5mU6QUPCRnHBKOacVnJK7VeuDt6Yt-oQZw2AGH8Oy6EwwT9hNwbIwwRW9GTax32yzj2182haxKQKOKc65t4Uf7OYTOW5Mm_HzoS7In58_fq9-lfcPN7er6_vSCiWHkivHxVphbdHYdaUUGCebxjDFKK6BOuOUwqbhYGvHlKA1rytQVNJGSImKL8jlfm-f4suIedCdzxbb1gSMY9aM1gIYo3JGL_5Dn-OYwvTdTAEwKSYRCyL3lE0x54SN7pPvTNpqoHqWrXey9WxSg9I72VpOc-eH7eO6Q_c29c_uBHzfAzjp-Osx6Ww9BovOJ7SDdtG_c-IVIUqNwA</recordid><startdate>20180801</startdate><enddate>20180801</enddate><creator>Steinhoff, Martin</creator><creator>Schmelz, Martin</creator><creator>Szabó, Imre Lőrinc</creator><creator>Oaklander, Anne Louise</creator><general>Elsevier Ltd</general><general>Elsevier Limited</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>0TZ</scope><scope>3V.</scope><scope>7RV</scope><scope>7TK</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>88G</scope><scope>8AO</scope><scope>8C2</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BENPR</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>GNUQQ</scope><scope>K9.</scope><scope>KB0</scope><scope>M0S</scope><scope>M1P</scope><scope>M2M</scope><scope>NAPCQ</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>PSYQQ</scope><scope>Q9U</scope><scope>7X8</scope></search><sort><creationdate>20180801</creationdate><title>Clinical presentation, management, and pathophysiology of neuropathic itch</title><author>Steinhoff, Martin ; Schmelz, Martin ; Szabó, Imre Lőrinc ; Oaklander, Anne Louise</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c485t-38d34b8e7ceacb6881ad5ffa2820eb10dad88eff31c7d2840737618050f455e83</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2018</creationdate><topic>Clinical trials</topic><topic>Cytokines</topic><topic>Dermatology</topic><topic>Diabetes mellitus</topic><topic>Diabetic neuropathy</topic><topic>Diagnosis</topic><topic>Disease Management</topic><topic>Drugs</topic><topic>Gastrin</topic><topic>Herpes zoster</topic><topic>Humans</topic><topic>Multiple sclerosis</topic><topic>Mutation</topic><topic>Narcotics</topic><topic>Nervous system</topic><topic>Neuralgia - diagnosis</topic><topic>Neuralgia - physiopathology</topic><topic>Neuralgia - therapy</topic><topic>Neurokinin</topic><topic>Neurokinin NK1 receptors</topic><topic>Peripheral neuropathy</topic><topic>Polyneuropathy</topic><topic>Pruritus</topic><topic>Pruritus - diagnosis</topic><topic>Pruritus - physiopathology</topic><topic>Pruritus - therapy</topic><topic>Skin</topic><topic>Ulcers</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Steinhoff, Martin</creatorcontrib><creatorcontrib>Schmelz, Martin</creatorcontrib><creatorcontrib>Szabó, Imre Lőrinc</creatorcontrib><creatorcontrib>Oaklander, Anne Louise</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Pharma and Biotech Premium PRO</collection><collection>ProQuest Central (Corporate)</collection><collection>Nursing &amp; Allied Health Database</collection><collection>Neurosciences Abstracts</collection><collection>Health &amp; Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>Psychology Database (Alumni)</collection><collection>ProQuest Pharma Collection</collection><collection>Lancet Titles</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central Essentials</collection><collection>ProQuest Central</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central Korea</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Central Student</collection><collection>ProQuest Health &amp; Medical Complete (Alumni)</collection><collection>Nursing &amp; Allied Health Database (Alumni Edition)</collection><collection>Health &amp; Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>ProQuest Psychology</collection><collection>Nursing &amp; Allied Health Premium</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>ProQuest One Psychology</collection><collection>ProQuest Central Basic</collection><collection>MEDLINE - Academic</collection><jtitle>Lancet neurology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Steinhoff, Martin</au><au>Schmelz, Martin</au><au>Szabó, Imre Lőrinc</au><au>Oaklander, Anne Louise</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Clinical presentation, management, and pathophysiology of neuropathic itch</atitle><jtitle>Lancet neurology</jtitle><addtitle>Lancet Neurol</addtitle><date>2018-08-01</date><risdate>2018</risdate><volume>17</volume><issue>8</issue><spage>709</spage><epage>720</epage><pages>709-720</pages><issn>1474-4422</issn><eissn>1474-4465</eissn><abstract>Unlike conventional itch, neuropathic itch develops in normal skin from excess peripheral firing or dampened central inhibition of itch pathway neurons. Neuropathic itch is a symptom of the same central and peripheral nervous system disorders that cause neuropathic pain, such as sensory polyneuropathy, radiculopathy, herpes zoster, stroke, or multiple sclerosis, and lesion location affects symptoms more than aetiology. The causes of neuropathic itch are heterogeneous, and thus diagnosis is based primarily on recognising characteristic, disease-specific clinical presentations. However, the diagnosis of neuropathic itch is challenging, different subforms exist (eg, focal vs widespread, peripheral vs central), and the mechanisms of neuropathic itch are poorly understood, resulting in reduced treatment availability. Currently available strategies include treating or preventing causal diseases, such as diabetes or herpes zoster, and topical or systemic medications that calm excess neuronal firing. Discovery of itch mediators such as gastrin releasing peptide, receptors (eg, neurokinin-1), and pathways (eg, Janus kinases) might encourage much needed new research into targeted treatments of neuropathic itch.</abstract><cop>England</cop><pub>Elsevier Ltd</pub><pmid>30033061</pmid><doi>10.1016/S1474-4422(18)30217-5</doi><tpages>12</tpages></addata></record>
fulltext fulltext
identifier ISSN: 1474-4422
ispartof Lancet neurology, 2018-08, Vol.17 (8), p.709-720
issn 1474-4422
1474-4465
language eng
recordid cdi_proquest_miscellaneous_2074122058
source MEDLINE; Elsevier ScienceDirect Journals
subjects Clinical trials
Cytokines
Dermatology
Diabetes mellitus
Diabetic neuropathy
Diagnosis
Disease Management
Drugs
Gastrin
Herpes zoster
Humans
Multiple sclerosis
Mutation
Narcotics
Nervous system
Neuralgia - diagnosis
Neuralgia - physiopathology
Neuralgia - therapy
Neurokinin
Neurokinin NK1 receptors
Peripheral neuropathy
Polyneuropathy
Pruritus
Pruritus - diagnosis
Pruritus - physiopathology
Pruritus - therapy
Skin
Ulcers
title Clinical presentation, management, and pathophysiology of neuropathic itch
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-07T20%3A36%3A49IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Clinical%20presentation,%20management,%20and%20pathophysiology%20of%20neuropathic%20itch&rft.jtitle=Lancet%20neurology&rft.au=Steinhoff,%20Martin&rft.date=2018-08-01&rft.volume=17&rft.issue=8&rft.spage=709&rft.epage=720&rft.pages=709-720&rft.issn=1474-4422&rft.eissn=1474-4465&rft_id=info:doi/10.1016/S1474-4422(18)30217-5&rft_dat=%3Cproquest_cross%3E2071125403%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2071125403&rft_id=info:pmid/30033061&rft_els_id=S1474442218302175&rfr_iscdi=true